文献速递乳腺技术与安全US

超声与微泡介导的病毒增敏药物递送改善体外溶瘤病毒治疗对乳腺癌细胞的效果

Ultrasound and Microbubble Mediated Delivery of Virus-Sensitizing Drugs Improves In Vitro Oncolytic Virotherapy Against Breast Cancer Cells.
PubMed 文献 · Ultrasound Med Biol · 2025-04-14

本研究将紫杉醇和沃拉色替负载于脂质微泡,利用超声空化在体外4T1小鼠乳腺癌细胞中递送药物以增强溶瘤水疱性口炎病毒感染。紫杉醇微泡包封率为83.7%、沃拉色替为28.6%;超声触发释放后病毒复制分别增加57倍(p<0.0001)和27倍(p<0.01),且载药微泡空化与游离药物增敏效果相当。

要点

  • 载紫杉醇与沃拉色替的脂质微泡经超声空化后显著增强溶瘤病毒在4T1细胞中的复制与杀伤。
  • 紫杉醇微泡包封率83.7%,沃拉色替微泡包封率28.6%。
  • 载药微泡空化与游离药物对癌细胞的病毒增敏效果相当。

核心结论

  • 载药微泡空化与游离药物均能使癌细胞对溶瘤病毒增敏至同等水平,为超声引导微泡药物递送联合溶瘤病毒治疗提供概念验证。

研究设计与样本

  • 体外研究,使用4T1小鼠乳腺癌细胞,将紫杉醇和沃拉色替负载于脂质微泡,经超声空化后评估对溶瘤水疱性口炎病毒感染的影响。

关键影像表现/征象

  • 载紫杉醇和沃拉色替的脂质微泡在多种条件下表现出优异的药物保留性。
  • 体外研究证实载药微泡具有声响应性,可在靶部位实现控释。

诊断标准与关键数值

  • 紫杉醇微泡包封率为83.7%,沃拉色替微泡包封率为28.6%。
  • 紫杉醇微泡超声触发空化后病毒复制增加57倍(p<0.0001)。
  • 沃拉色替微泡超声触发空化后病毒复制增加27倍(p<0.01)。

临床应用与阅片要点

  • 载药微泡空化与游离药物对癌细胞的病毒增敏效果相当,支持超声引导微泡递送联合溶瘤病毒治疗的概念验证。

局限性

  • 本研究为体外研究,结论基于4T1乳腺癌细胞模型。
  • 原文指出这些发现仅为概念验证,需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: Oncolytic virotherapy is an emerging form of cancer treatment that uses replication-competent viruses to kill cancer cells. However, as for other cancer therapies, oncolytic viruses are not effective against all cancers and there is a need to further improve treatment efficacy while maintaining low toxicity. Viral sensitizers are drugs that potentiate viral replication in tumor cells. While various studies have shown their synergy with oncolytic virotherapy, the risks associated with systemic toxicities that vary according to the drug used limit the clinical translation of the approach. In this study, we used an ultrasound and image-guided approach in which we loaded viral-sensitizing drugs onto microbubbles which are then cavitated by ultrasound to deliver the encapsulated drugs to tumor cells, which improves in vitro oncolytic virotherapy efficacy in the 4T1 breast cancer model.

METHODS: In this study, we loaded two viral sensitizers, paclitaxel and volasertib, onto lipid microbubbles and comprehensively characterized their effect on the infection of 4T1 murine mammary carcinoma cells by oncolytic Vesicular stomatitis virus in vitro.

RESULTS: We synthesized lipid microbubbles with high and moderate encapsulation efficiency for paclitaxel (83.7%) and volasertib (28.6%), respectively. Stability assessments demonstrated excellent retention in various conditions, highlighting their potential for in vivo use. In vitro studies confirmed their acoustic responsiveness essential for controlled drug release at targeted sites. Paclitaxel and volasertib release from viral sensitizer-loaded microbubbles following ultrasound-triggered cavitation significantly increased viral replication (57-fold, p < 0.0001 and 27-fold, p < 0.01, respectively), as well as tumor cell killing compared to virus-infected untreated cells.

CONCLUSION: Altogether, our data show that drug-loaded microbubble cavitation and free drugs both sensitize cancer cells to oncolytic viruses to equivalent levels. These findings provide a proof of concept for the use of ultrasound-guided microbubble drug delivery in combination with oncolytic virotherapy.

来源:Ultrasound Med Biol,查看原文。版权归原作者所有。

引用

  1. Italiya KS, Mullins-Dansereau V, Geoffroy K, et al. Ultrasound and Microbubble Mediated Delivery of Virus-Sensitizing Drugs Improves In Vitro Oncolytic Virotherapy Against Breast Cancer Cells. Ultrasound Med Biol. 2025. PMID: 40234152. doi:10.1016/j.ultrasmedbio.2025.03.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。